Efficacies ofDifferent Vancomycin Dosing Regimens against Staphylococcus aureusDetermined with a Dynamic InVitro Model (original) (raw)
Concentration–response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model
Irene Lubenko
International Journal of Antimicrobial Agents, 2007
View PDFchevron_right
Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus
Ellie Hershberger
Antimicrobial agents and chemotherapy, 1999
View PDFchevron_right
Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration
Kátia Regina dos Santos
2019
View PDFchevron_right
Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections
Catherine M T Sherwin
Expert Review of Anti-infective Therapy, 2014
View PDFchevron_right
Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia
Alan Forrest
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model
Glenn Kaatz
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
In Vitro Studies of Pharmacodynamic Properties of Vancomycin against Staphylococcus aureus and Staphylococcus epidermidis
Inga Odenholt
Antimicrobial Agents and Chemotherapy, 1998
View PDFchevron_right
Vancomycin minimum inhibitory concentrations using different susceptibility methods in Staphylococcus aureus isolates
Thaina Costa
The Journal of Infection in Developing Countries, 2014
View PDFchevron_right
Vancomycin and Piperacillin-Tazobactam Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Thomas Dilworth
Clinical Therapeutics, 2014
View PDFchevron_right
Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia
Jerome Schentag
Antimicrobial Agents and Chemotherapy, 2007
View PDFchevron_right
Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model
Irene Lubenko
2008
View PDFchevron_right
Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?
George Drusano
Antimicrobial Agents and Chemotherapy, 2014
View PDFchevron_right
Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists
John Rotschafer
Clinical Infectious Diseases, 2009
View PDFchevron_right
Vancomycin loading dose is associated with increased early clinical response without attainment of initial target trough concentration at a steady state in patients with methicillin‐resistant Staphylococcus aureus infections
Yoshio Takesue
Journal of Clinical Pharmacy and Therapeutics, 2020
View PDFchevron_right
Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation: PK/PD analysis of vancomycin dosing in ICU patients
NATALIA REVILLA
British Journal of Clinical Pharmacology, 2010
View PDFchevron_right
Vancomycin Dosing: Assessment of Time to Therapeutic Concentration and Predictive Accuracy of Pharmacokinetic Modeling Software
Cecile Aubron, Carmela Corallo
Annals of Pharmacotherapy, 2011
View PDFchevron_right
Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Jose William Martínez
Clinical Infectious Diseases, 2008
View PDFchevron_right
Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model
John Rotschafer
Antimicrobial Agents and Chemotherapy, 1990
View PDFchevron_right
Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation
Ana Martín Suárez
British Journal of Clinical Pharmacology, 2010
View PDFchevron_right
Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus
Natalia González
International Journal of Antimicrobial Agents, 2011
View PDFchevron_right
Evaluation of the Relationship Between Elevated Vancomycin Trough Concentrations and Increased Efficacy and/or Toxicity
Linwood Haith
Journal of Burn Care & Research, 2013
View PDFchevron_right
In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin
Glenn Kaatz
Antimicrobial Agents and Chemotherapy, 1992
View PDFchevron_right
Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus
Paul Hutson
Journal of Antimicrobial Chemotherapy, 2010
View PDFchevron_right
Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing
Michael Van Guilder
Antimicrobial agents and chemotherapy, 2018
View PDFchevron_right
Comparison of Vancomycin Treatment Failures for Methicillin-Resistant Staphylococcus aureus Bacteremia Stratified by Minimum Inhibitory Concentration
Yusri Juma
Journal of Pharmacy Technology, 2019
View PDFchevron_right